Cargando…

Clinical Outcomes of Patient Subgroups in the TANGO II Study

INTRODUCTION: Meropenem–vaborbactam (M-V), a new approved antimicrobial, was developed specifically to be effective treatment for the increasingly prevalent and difficult to treat carbapenem-resistant Enterobacterales (CRE) infections. However, registration phase 3 clinical studies offer limited app...

Descripción completa

Detalles Bibliográficos
Autor principal: Bhowmick, Tanaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872113/
https://www.ncbi.nlm.nih.gov/pubmed/33565042
http://dx.doi.org/10.1007/s40121-021-00405-x